RFK Jr.’s pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK’s plans to cut D2C advertising.
Trump plans to “knock out” pharma’s middlemen: His comments sent shares of the three largest pharmacy benefit managers down in a sign of what’s to come under the incoming administration.
Health systems partner with wellness brands for digital advertising: We explore how legacy healthcare providers are offering health and wellness brands ad placements on their digital platforms to drive revenue and connect patients with medical products and services.
Dexcom launches genAI platform: Integrating its over-the-counter continuous glucose monitor with genAI is likely a test-case to work out any kinks before a wider rollout to those using its legacy products.
Patients have mixed opinions of healthcare tech: Healthcare organizations and marketers will need to keep innovating without compromising the patient experience.
The data: Nurses remain skeptical of the impact that AI will have in healthcare settings, according to Jarrard’s 2024 Nurse Survey Report. Some 837 US nurses were surveyed in September 2024.
Amazon’s biggest healthcare moves in 2024: Amazon has prioritized connecting Prime members with healthcare and pharmacy services. We examine which of its health-focused developments could be most impactful.
Consumers struggle to stick with healthy behaviors: There’s a disconnect between intent and behavior as consumers work to incorporate healthier habits into their daily routines. We discuss the opportunity for health marketers to close this gap.
CVS’ biggest healthcare moves in 2024: Eyeing a return to profitability for Aetna, the company prioritized cost-cutting measures and new leadership. We examine which of its health-focused moves could ultimately have the biggest impact on its bottom line.
Healthcare and pharma companies will lean further into D2C in 2025: They’re cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry’s push into D2C won’t be met without challenges.
The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what’s at stake for drugmakers and D2C companies selling compounded weight loss medications.
Digital health funding deal size steadied over the last two quarters: But with investors continuing to lean into a cautious spending approach, we expect startups’ funding woes to persist into 2025.
The high cost of healthcare will affect consumer behavior in 2025: Consumers are shopping around for health products and services, presenting companies with an opportunity to differentiate themselves by prioritizing customer service.
Walgreens’ biggest healthcare moves in 2024: Amid a brutal year trying and failing to achieve profitability, the company prioritized operating with a leaner business profile and is even considering a sale.
Many Vermonters can’t afford or access healthcare, even though most are insured: The issue isn’t lack of insurance, but rather underinsurance. We highlight this growing problem plaguing consumers across the US.
Social media fuels micro-dosing trend with Ozempic: The trend speaks to the power of social health influencers, but emphasizes responsibility to marketers who need to make sure consumers are getting the most accurate drug information on the channel.
Our top healthcare and pharma stories of 2024: Readers engaged with our stories on consumers’ health and wellness spending, pharma marketing to doctors, healthcare information on TikTok, and Trump’s impact on drugmakers.
FTC warns ACA marketplace insurance marketers about deceptive claims: The warnings come during open enrollment season, a period that typically creates confusion among consumers.
Consumers and physicians disagree on the value of health wearables: If wearable makers are able to foster physician trust in the data generated by their devices, they could gain an edge in uptake from consumers eager to share their health data.
Americans support some of Trump and RFK’s healthcare plans, oppose others: But people in the US distrust the leaders as reliable health sources. Healthcare and pharma stakeholders must place a premium on delivering credible information to the public as the new administration takes shape.